Loading in 2 Seconds...
Loading in 2 Seconds...
The latest market report published by Credence Research, Inc. “Global Carcinoembryonic Antigen\n(CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 -\n2023,” the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
“Carcinoembryonic Antigen (CEA) Market- Growth, Share, Opportunities,
Competitive Analysis, and Forecast 2016 – 2023”
The latest market report published by Credence Research, Inc. “GlobalCarcinoembryonic Antigen
(CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 -
2023,” the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is
expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.
Browse the full report Carcinoembryonic Antigen (CEA) Market - Growth, Share,
According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract
and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal
cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market
experts suggest that key growth drivers assisting the growth of CEA market comprises high
prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive
diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of
cancer. In addition, a few factors that assist the overall market growth are growing healthcare
expenditure which is boosting the need for efficient diagnostic procedure for cancer and influencing
the usage of combination biomarkers.
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into
ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and
other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of
revenue. The key factors responsible for growth of CEA market are increase in number of population
consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover,
rising preference for CEA test in cancer diagnosis and management is expected to assist its market
growth in the near future.
In base year 2015, North America was observed as the largest CEA market due to high public
awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis
tests and sophisticated health care facilities for cancer management. Incessant technological
developments followed by new discoveries of specific antigens and biomarkers are anticipated to
boost the growth of CEA market testing. The key factors assisting the growth of CEA market
comprises aging population, highly accessible technologically advanced healthcare facilities,
successful governmental and non-governmental initiatives, and demand for precise diagnostic
Market Competition Assessment:
The carcinoembryonic antigen (CEA) market is observed as the most diversified and competitive
market comprising large number of players. The market is dominated by several players, depending
on their major competencies. The key players in this market are Quest Diagnostics, F. Hoffman LA
Roche, Abbott Laboratories, GenWay Biotech Inc., Correlogic Systems, Inc., and Others.
Browse the full Carcinoembryonic Antigen (CEA) Market - Growth, Future Prospects and Competitive
Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-
Credence Research is a worldwide market research and counseling firm that serves driving organizations,
governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with
making enduring enhancements to their execution and understand their most imperative objectives. Over almost
a century, we've manufactured a firm extraordinarily prepared for this task.
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US